Overall, a lower number of studies are currently available discussing the impact of obesity on anti‐IL‐17 or anti‐IL‐23 with respect to TNF inhibitors, and the differences in response between obese and nonobese patients resulted less prominent [60]. The gene discussed is IL17A; the disease is obesity due to melanocortin 4 receptor deficiency.